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H727 cells are inherently resistant 
to the proteasome inhibitor 
carfilzomib, yet require proteasome 
activity for cell survival and growth
Min Jae Lee1, Zachary Miller1, Ji Eun Park2, Deepak Bhattarai1, Wooin Lee  2 & Kyung Bo Kim1
The second-in-class proteasome inhibitor (PI) carfilzomib (Kyprolis, Cfz) has contributed to a 
substantial advancement in multiple myeloma treatment by improving patient survival and quality 
of life. A considerable portion of patients however display intrinsic resistance to Cfz. Our mechanistic 
understanding of intrinsic Cfz resistance is limited due to a lack of suitable cell-based models. We 
report that H727 human bronchial carcinoid cells are inherently resistant to Cfz, yet susceptible to 
other PIs and inhibitors targeting upstream components of the ubiquitin-proteasome system (UPS). 
These results indicate that H727 cells remain dependent on the UPS for cell survival and growth despite 
harboring intrinsic resistance to Cfz. Alterations in the composition of proteasome catalytic subunits via 
interferon-γ treatment or siRNA knockdown results in sensitization of H727 cells to Cfz. We postulate 
that a potential link may exist between the composition of proteasome catalytic subunits and the 
cellular response to Cfz. Overall, H727 cells may serve as a useful cell-based model for de novo Cfz 
resistance and our results suggest previously unexplored mechanisms of de novo PI resistance.
The proteasome, an evolutionarily conserved multiprotease complex, is responsible for the controlled degra-
dation of intracellular proteins. These include defective ribosomal products (DRiPs), oxidized proteins, and 
tightly-regulated cellular signaling proteins involved in cell cycle progression, immune response, apoptosis, signal 
transduction, and stress responses1. Proteins are targeted for proteasomal degradation by ubiquitination, a pro-
cess involving a cascade of three enzymes: E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), 
and E3 (ubiquitin ligase). Once protein substrates are polyubiquitinated, they are recognized by the proteasome’s 
regulatory particle (19S complex) and degraded within the central chamber of the core particle (20S complex) 
of the proteasome. The 20S proteasome core is composed of four stacked heptameric rings: two outer α-rings 
and two inner β-rings. In mammalian proteasomes, each β-ring harbors three catalytic β-subunits, β1, β2, and 
β5 which display different substrate preferences, respectively referred to as caspase-like (C-L), trypsin-like (T-L) 
and chymotrypsin-like (CT-L) activities. It was generally thought that 20S proteasomes exist in two main types, 
namely, the constitutive proteasome (cP) and the immunoproteasome (iP). Immunoproteasomes differ from cP 
by the replacement of β1, β2, and β5 with the homologous catalytic subunits β1i, β2i, and β5i. Interestingly, recent 
investigations revealed that certain tissues and some cancer cells carry non-standard types of 20S proteasomes 
(referred to as hybrid or intermediate proteasomes), which contain mixed assortments of cP and iP catalytic 
subunits, such as β1i-β2-β5i2–6. It was further reported that these non-standard proteasomes may confer differing 
sensitivities to proteasome inhibitors (PIs) as compared to cPs or iPs4,5,7, but the clinical implications of these 
non-standard proteasomes remain unknown.
The proteasome is an effective anticancer target, validated by the clinical success of the FDA approved pro-
teasome inhibitors (PIs) bortezomib (Velcade, Btz), carfilzomib (Kyprolis, Cfz), and ixazomib (Ninlaro, Ixz) as 
multiple myeloma (MM) therapies. PIs have become an integral part of MM treatment and have contributed to 
a major uplift of patient outcomes over the past decade and a half. While the first-in-class PI drug Btz and the 
first oral PI Ixz utilize boronic acid pharmacophores, the second-generation PI Cfz harbors an epoxyketone that 
irreversibly inactivates the proteasome with high mechanistic selectivity8,9. This selectivity affords Cfz a reduction 
1Department of Pharmaceutical Sciences, University of Kentucky, Lexington, KY, USA. 2college of Pharmacy 
and Research institute of Pharmaceutical Sciences, Seoul national University, Seoul, Korea. correspondence and 
requests for materials should be addressed to K.B.K. (email: kbkim2@uky.edu)
Received: 6 November 2018
Accepted: 20 February 2019
Published: xx xx xxxx
OPEN
2Scientific RepoRts |          (2019) 9:4089  | https://doi.org/10.1038/s41598-019-40635-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
in off-target interactions yielding an improved safety profile over Btz, most notably a reduced incidence of severe 
peripheral neuropathy10. With positive results from recent phase III clinical trials11–16, Cfz is now firmly placed 
as a mainstay of refractory MM therapy. Nevertheless, a considerable portion of MM patients are refractory to 
Cfz or develop resistance after prolonged Cfz treatment. A meta-analysis of 14 clinical trials found that 44% of 
patients could not achieve a minimal response or better17. As a monotherapy in patients with relapsed MM, for 
example, the response rates for Cfz were in the ranges of 25–40%18. When used in combination with other drugs 
(often with dexamethasone and/or lenalidomide), response rates substantially improved, but a significant subset 
of non-responders persisted16,19–22. Even for those who initially respond to Cfz-based therapy, disease eventually 
relapses with a median progression-free-survival (PFS) of ~17–26 months20,21. To date, considerable efforts have 
been put forth toward the development of new therapeutics for these Cfz non-responders without significant pro-
gress. Efforts to tackle this problem have been significantly hampered by a limited understanding of the biological 
mechanisms underlying Cfz resistance.
Mechanistic investigations of Cfz resistance have so far utilized cancer cell lines adapted to gradually increas-
ing concentrations of Cfz, revealing that the overexpression of P-glycoprotein (P-gp) and mutations or amplifica-
tion/overexpression of proteasome catalytic subunits are largely responsible for acquired Cfz resistance observed 
in established cell lines23–25. To date, cell-based models of de novo Cfz resistance are unavailable. Here, we report 
for the first time that H727 cells (derived from a human bronchial carcinoid tumor) are inherently resistant to Cfz, 
yet remain dependent on the proteasome for their survival and growth. Our current results suggest that de novo 
Cfz resistance observed in H727 cells may be mediated at the 20S proteasome level, providing previously 
unknown insights into the mechanisms of de novo PI resistance.
Results
H727 cells are inherently resistant to Cfz. When the IC50 values for Cfz were assessed in a panel of 21 
human cancer cell lines derived from various types of cancer, H727 lung cancer cells were most resistant to Cfz, 
with a IC50 value of 610 nM (Fig. 1a). Even in the presence of 250 nM of Cfz which usually induces >95% loss 
of viability in other cancer cell lines, H727 cells survived and grew normally (Fig. 1b; the relative cell viability 
on day 3 was 88.1% based on the counting of cells not stained with trypan blue dye (Sigma-Aldrich, St. Louis, 
MO)). While the mechanisms of intrinsic resistance to Cfz has not been reported to date, several studies have 
shown that P-gp can contribute to acquired resistance to Cfz observed in cancer cell line models and clinical 
samples from patients with prior Cfz therapy24,26,27. To test whether P-gp plays a role in the de novo Cfz resist-
ance of H727 cells, we performed immunoblotting analysis but found no detectable P-gp expression (Fig. 1c). 
Figure 1. (a) Cell viability (IC50 values) for a panel of established cancer cell lines as measured by MTS assay 
following incubation with carfilzomib (Cfz) for 72 h. H727 cells are most resistant to Cfz among 21 tested 
cell lines. (b) Representative images of H727 cells growing in the presence of Cfz (250 nM) assessed via light 
microscopy. On day 3 of Cfz treatment, live cell not stained with trypan blue were counted (expressed as % 
cell viability relative to the vehicle control; no statistically significant difference between Cfz-treated H727 
cells and the vehicle control by Student’s t-test, P value > 0.1, n = 3). (c) Immunoblotting results showing no 
detectable expression of P-glycoprotein (P-gp) in H727 cells. DLD-1 cells with acquired Cfz resistance via P-gp 
upregulation (DLD-1/CfzR) were used as a positive control. (d) The co-treatment of reversin-121 (7.5 µM, P-gp 
inhibitor) did not affect the sensitivity of H727 cells to Cfz. The IC50 values did not show statistically significant 
difference between in the presence and absence of reversin-121 (Student’s t-test). (e) The levels of remaining Cfz 
in culture media were comparable between H727 and H23 cells (no statistically significant differences, t-tests 
the Holm-Sidak method to correct for multiple comparisons with α = 0.05).
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Furthermore, treatment of H727 cells with reversin 121, a dipeptide P-gp inhibitor, did not significantly impact 
the IC50 value of Cfz (Fig. 1d), confirming a P-gp-independent mechanism of resistance. Direct sequencing anal-
yses also indicated that the PSMB5 (encoding β5) and PSMB8 (encoding β5i) genes in H727 cells harbor no 
mutations (Supplementary Fig. S1). Next, we examined the possibility that Cfz may undergo rapid metabolic 
inactivation in H727 cells. We treated H727 and H23 (Cfz-sensitive) cells with 500 nM Cfz and collected culture 
media to measure the levels of remaining Cfz at 6 or 24 h post-treatment. The level of remaining drug was overall 
comparable between H727 and H23 cells although a slight difference was noted at 24 h (Fig. 1e). We attempted to 
compare the intracellular drug levels by quantifying the remaining drug levels in lysates of H727 and H23 cells, 
but the levels were below the lower limit of quantitation (<5 nM) of our current analytical assay. Although it 
was not feasible to assess the intracellular drug levels, H727 cells contained Cfz in the culture media at the level 
comparable to or slightly higher than H23 cells. Assuming that Cfz primarily enters cells via passive diffusion (no 
report yet supporting the presence of uptake transporters for Cfz as far as we know), it appears unlikely that H727 
cells have intracellular Cfz levels much lower than H23 cells. Taken together, de novo resistance of H727 cells was 
not explained by previously reported mechanisms such as P-gp upregulation, genetic mutations in proteasome 
catalytic subunits, or enhanced metabolic inactivation of Cfz.
The UPS/proteasome remains essential for the survival of H727 cells. Cfz selectively inhibits the 
proteasome by covalently modifying the N-terminal catalytic threonine residues of 20S proteasome catalytic sub-
units at nanomolar concentrations while not inhibiting other proteases at concentrations as high as 50 µM8,28,29. 
We thus considered whether H727 cells might have adaptations to endure reduced levels of 20S proteasome 
function, for example, the use of non-proteasomal protein degradation pathways thus reducing proteasome load. 
In order to determine whether the 20S proteasome is essential for the survival and growth of H727 cells as it is in 
Cfz-sensitive cell lines such as H23, we first transfected cells with siRNAs targeting the proteasome α7 subunit to 
block 20S proteasome assembly (Fig. 2a,b)30,31. After 3 days post-transfection, we observed nearly complete cell 
death for both H727 and H23 cells (Fig. 2b). The extent and time-course of cell death incurred by α7 knockdown 
was comparable between H727 and H23 cells, indicating that H727 cells are highly dependent on the 20S protea-
some. These results suggested that H727 cells may still respond to proteasome inhibitors other than Cfz. In order 
to examine this, we treated H727 cells with alternative PIs, particularly ones with differing pharmacophores or 
structures, such as Btz (a peptide boronic acid) and MG-132 (a peptide aldehyde). These PIs were indeed highly 
Figure 2. (a) Diagram showing the ubiquitin-proteasome system (UPS) and inhibitors targeting upstream 
components of the proteasome. (b) Knockdown of proteasome α7 subunit in H727 cells effectively induced 
cell death to a similar extent as observed in H23 cells (images taken 48 h post-transfection). Immunoblotting 
analysis was performed to verify the efficient knockdown of α7 in H727 cells. (c) Comparison of the sensitivity 
(IC50 values) of H727 and H23 cells to carfilzomib, bortezomib, MG-132, PYR-41 (an E1 inhibitor) and P5091 
(an USP7/USP47 inhibitor). Data are shown as mean ± SD derived from a single non-linear regression based on 
n = 3–4 replicates per compound per concentration.
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effective in killing H727 cells and their IC50 values were comparable between H727 and H23 cells (Fig. 2c). We 
also used two inhibitors targeting non-proteasomal UPS components: PYR-41, an inhibitor of ubiquitin E1 ligase 
and several DUBs, and P5091, a specific USP7/USP47 inhibitor32. Both PYR-41 and P5091 were cytotoxic in 
H727 and H23 cells with comparable potencies (Fig. 2c). These results further support that H727 cells remain 
dependent on the ubiquitin-proteasome system, despite their de novo resistance to Cfz.
H727 cells have a distinct composition of proteasome catalytic subunits. To account for the sen-
sitivity of H727 cells to other PIs, we hypothesized whether the subunit composition at the 20S proteasome level 
may contribute to de novo resistance of H727 cells to Cfz. To test this hypothesis, we compared the proteasome 
catalytic subunit expression and activity profiles of H727 and H23 cells via immunoblotting analysis and kinetics 
assays using fluorogenic substrates for individual subunits (β1, β5, β1i, β5i). In the case of the β2 and β2i subunits, 
their combined trypsin-like activity was assessed due to the lack of a specific fluorogenic substrate that can dis-
tinguish the two subunits. As shown in Fig. 3a, the expression pattern of proteasome catalytic subunits in H727 
cells differed from that in H23 cells. H727 cells expressed high levels of β1, β2, and β5i, while β1i expression was 
undetectable. The expression profile of catalytic subunits in H727 cells was not consistent with those typically 
expected for the two main 20S proteasome subtypes, namely a set of β1-β2-β5 for cP or an immuno-subunit 
set of β1i-β2i-β5i for iP. Substantial differences were also noted when the activity profiles of proteasome cata-
lytic subunits were compared between these two cell lines using subunit-selective fluorogenic substrates (Fig. 3b, 
the relative hydrolysis rates for each probe substrate shown as a heat map and numbers)33. Interestingly, the 
activity profiles of individual catalytic subunits showed discrepancies with the protein levels of the respective 
catalytic subunits. We suspect that the observed differences may reflect the complex relationship between pro-
teasome structure and function (e.g. contributions of post-translational modifications, regulatory particles, or 
non-standard composition of proteasome catalytic subunits to the hydrolysis rates of fluorogenic substrates).
We next examined whether individual subunits of proteasomes in H727 cells may display different proteasome 
inhibition profiles than those of H23 cells. We treated H727 and H23 cells with 20 nM of Cfz for 4 h and meas-
ured the remaining activities of individual catalytic subunits relative to vehicle-treated control cells. As shown 
in Fig. 3c (left panel), more than 80% of β5, β5i and β1i activities were blocked by Cfz for both H727 and H23 
Figure 3. (a) Immunoblots showing the expression of cP and iP catalytic subunits in H727 and H23 cells. 
Immunoblots for additional cell lines displaying differential expression of proteasome catalytic subunits are 
presented in Supplementary Fig. S2. (b) Heat map displaying differential proteasome activity profiles in H727 
and H23 cell lines. Purified human 20S cP and iP were used as controls for individual subunits: 20S cP for β5 and 
β1 and 20S iP for β5i and β1i. The numbers represent hydrolysis rates of respective substrates (RFU/min, mean 
values derived from three technical replicates) and were converted to color format and clustered by using the 
program “R” (http://www.R-project.org). (c) Remaining catalytic activities of individual proteasome subunits in 
H727 and H23 cells 4 h after treatment with 20 nM of carfilzomib (left panel) or 20 nM bortezomib (right panel). 
Data are presented as mean ± SD derived from three technical replicates.
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cells. On the contrary, over 50% of β1 activity persisted in H727 cells, but not in H23 cells (Fig. 3c, left panel). It 
remains unclear whether the remaining β1 activity contributes to de novo resistance of H727 cells to Cfz. On the 
other hand, Btz treatment resulted in over 80% inhibition across all catalytic subunits in both H727 and H23 cell 
lines, which may explain the high sensitivity of both cell lines to Btz (Fig. 3c, right panel). These results support 
that the 20S proteasomes present in H727 cells may be functionally different from those in Cfz-sensitive H23 cells.
Upregulation of β1i and β5i levels by IFN-γ sensitizes H727 cells to Cfz. Based on the differential 
expression pattern of proteasome catalytic subunits in H727 as compared to H23, we hypothesized that the com-
position of proteasome catalytic subunits may impact the sensitivity of H727 cells to Cfz. To test this hypothesis, 
we altered catalytic subunit composition in H727 using interferon-γ (IFN-γ) treatment. IFN-γ’s ability to upregu-
late immuno-subunits (β1i, β2i, and β5i) and to induce IP formation has been well-documented34–38. As shown in 
Fig. 4a, incubation of H727 cells with IFN-γ (150 U⋅ml−1) 24 h prior to Cfz treatment resulted in upregulation of 
immuno-subunit expression and corresponding increases in their activity. IFN-γ pre-treatment caused a significant 
decrease in Cfz IC50 values from 621.1 to 189.5 nM in H727 cells. When H23 cells were pre-treated with IFN-γ, the 
Cfz IC50 values changed in the opposite direction (IC50 values increased from 18.6 to 44.1 nM, Fig. 4b). With IFN-γ 
pre-treatment, the fold differences in IC50 values between the two cell lines were reduced from 33-fold to 4.2-fold.
Alteration of proteasome catalytic subunit composition affects H727 Cfz sensitivity. In order to 
further investigate a causal relationship between the composition of proteasome catalytic subunits and Cfz sensitivity, 
we sought to alter the composition of proteasome catalytic subunits in H727 cells in a more selective manner using 
an siRNA pool targeting the abundantly expressed β5 subunit. We expected that β5i will substitute for β5 during pro-
teasome assembly, forming 20S complexes with altered catalytic subunit composition. When β5 was knocked down 
(verified via immunoblotting and activity assays, Fig. 5a,b), H727 cells grew normally with modest upregulation of β5i. 
Despite their normal growth, H727 cells were significantly sensitized to Cfz by β5 knockdown, shifting the IC50 value 
from 622 to 99.9 nM (Fig. 5c). In contrast, the IC50 for Btz was only modestly affected, decreasing from 26 to 12 nM 
(Supplementary Fig. S3). Knockdown of other catalytic subunits such as β5i and β2 resulted in minimal changes in the 
IC50 values for Cfz. A similar pattern was observed in H23 cells where knockdown of β5i and β2 had little effect on Cfz 
sensitivity but β5 knockdown triggered a five-fold reduction in Cfz IC50 from 26.7 to 5.0 nM (Fig. 5c).
Inter-patient variability in the proteasome activity profiles of primary MM cells is high. In order to 
assess whether the observed variability in proteasome activity profiles in PI-naïve cell line models reflects the Cfz sen-
sitivity of clinical MM samples, we examined the proteasome activity profiles and degree of Cfz sensitivity using 6 MM 
samples from patients who have received no prior PI therapy. Similar to the results obtained using cell line models, the 
clinical samples also showed considerable variability in catalytic subunit activity profiles and Cfz sensitivity (Fig. 5d). 
Due to the limited sample quantities, we were not able to perform any further investigations on these samples. Based on 
these initial assessment, we cautiously speculate that differential Cfz sensitivity in these patient samples may be influ-
enced by variability in proteasome catalytic subunit composition, perhaps partially accounting for the varied responses 
to Cfz observed in clinical trial results11,15,20.
Figure 4. Effect of IFN-γ pretreatment on carfilzomib sensitivity of H727 (a) and H23 (b) cells. IFN-γ  
(150 U⋅ml−1) pretreatment for 24 h led to increased expression (left panel) and activity (middle panel) of proteasome 
immuno-subunits, and sensitized H727 cells to Cfz, while desensitizing H23 cells towards Cfz. The IC50 values 
displayed a statistically significant difference between IFN-γ-pretreated cells and vehicle control (P value < 0.01, n = 3, 
Student’s t-test comparing the log transformed IC50 values obtained from three independent runs).
6Scientific RepoRts |          (2019) 9:4089  | https://doi.org/10.1038/s41598-019-40635-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
Discussion
The advent of Cfz therapy has improved outcomes for many MM patients. However, like many other anticancer 
agents, the successful clinical use of Cfz is significantly challenged by the presence of intrinsic and acquired 
drug resistance. A significant fraction of MM patients previously treated with Btz-containing regimens do not 
respond to Cfz and even those who initially respond to Cfz almost invariably develop resistance in the course 
of their treatment11,17,39. In order to design new and effective therapeutic strategies which avoid, eliminate, or 
bypass resistance, it is important to better understand the mechanisms of Cfz resistance. To date, investigations 
of Cfz resistance have largely focused on acquired resistance due to the relative ease of generating Cfz-adapted 
cancer cell lines and the availability of clinical samples derived from patients who have developed resistance 
after prolonged Cfz therapy. On the other hand, mechanistic investigations of de novo Cfz resistance have been 
scarce, due to the lack of appropriate cell line models and patient samples. In the current study, we report that 
H727 cells are intrinsically resistant to Cfz, potentially serving as a useful model for mechanistic investigations of 
de novo Cfz resistance. Given that H727 cells were sensitive to inhibitors of non-proteasomal targets in the UPS 
and PIs other than Cfz, we surmise that H727 cells harbor functionally active proteasomes and that complete or 
near-complete inhibition of proteasome catalytic activity is incompatible with survival in these cells. Based on our 
current results, a shift towards non-UPS protein degradation pathways appears unlikely since H727 cells remain 
highly sensitive to the inhibition of UPS components including the proteasome itself.
Despite their similar degrees of dependence on the proteasome or UPS for survival and growth, H727 and 
H23 cells respond differently to Cfz, to a degree of 33-fold difference in IC50 values. This may be in part due to 
cell line-dependent cell growth rates or genetic/molecular differences. However, the high sensitivity of H727 cells 
to other PIs suggests that Cfz resistance in H727 cells may be mediated at the 20S proteasome level. It has been 
reported that proteasome inhibitor resistance is often associated with increased levels of proteasome subunit 
catalytic activity, especially in models of acquired bortezomib resistance40,41. However, H727 cells displayed sub-
stantially low activities of individual catalytic subunits as compared to H23 cells. At present, it is unclear whether 
the low proteasome activities in H727 cells are involved in conferring Cfz resistance. Previously it was reported 
that 20S proteasomes harboring a mixed assortment of cP and iP catalytic subunits exist in cancer cells and that 
their PI sensitivity differs from those of standard cP or iP5. Our results also indicated not only differing expression 
levels of proteasome catalytic subunits between H727 and H23 cells, but also differing levels of subunit catalytic 
activity. These findings are consistent with the presence of non-standard 20S proteasome subtypes (other than cP 
Figure 5. (a) Immunoblots of proteasome catalytic subunits in H727 cells transfected with siRNA targeting β5, 
β2 or β5i. (b) The catalytic activity of β5 subunit was decreased in H727 cells transfected with siRNA targeting 
β5 compared with H727 cells transfected with scrambled siRNA. (c) Effects of siRNA knockdown of β5, β5i, 
or β2 on Cfz sensitivity (IC50 values) in H23 and H727 cells. Data are shown as mean ± SD derived from a 
single non-linear regression based on n = 3 replicates per compound per concentration. (d) Heat map showing 
proteasome catalytic subunit activity profiles of 6 PI-naïve patient MM samples purchased from Conversant 
Biologics and AllCells (left). The numbers represent hydrolysis rates of respective substrates (RFU/min, mean 
values derived from three technical replicates) and were converted to color format and clustered by using the 
program “R” (http://www.R-project.org) (left panel). Carfilzomib (Cfz) cell viability of the same 6 patient MM 
cells was measured via CellTiter-Glo Luminescent Cell Viability Assay (right panel).
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and iP). Determination of the 20S proteasome subtypes present in H727 cancer cells may shed further light on 
the underlying mechanisms of de novo Cfz resistance in H727 cells. Determination of the subunit composition of 
intact 20S proteasomes in cells is challenging and several groups including ours are currently trying to develop 
bi-functional or fluorescent probes to facilitate these efforts33,42,43.
In summary, we show here that H727 cancer cells are intrinsically resistant to Cfz but remain dependent on 
the proteasome for their survival and growth. Current mechanistic studies suggest that the composition of protea-
some catalytic subunits may play an important role in determining sensitivity to Cfz. Our study also implies that 
proteasome inhibition by alternative PIs may still be a valid therapeutic strategy for patients with relapsed MM 
after having received treatment with Cfz.
Materials and Methods
Cell lines and chemicals. MDA-MB-231, HCC1143, and HCC1937 breast cancer cells were purchased from 
the Korean Cell Line Bank (Seoul, Korea). Hep3B, Huh7, LCSC, HepG2, and PLC/PRF/5 hepatic cancer cells 
were a kind gift of Dr. Roberto Gedaly (College of Medicine, University of Kentucky). All other established cell 
lines were obtained from the American Type Culture Collection (ATCC, Rockville, MD). All cells were cultured 
according to the manufacturer’s protocol in 5% CO2 in medium. Cultured cell lines were tested for Mycoplasma 
contamination routinely every 6 months. Specifically, H23 and H727 cells were tested twice in the course of per-
forming the experiments described within this publication (Supplementary Fig. S4). Inhibitors of UPS pathways 
used in this study were purchased from commercial vendors: carfilzomib (LC Laboratories, Woburn, MA), borte-
zomib (ChemieTek, Indianapolis, IN), MG-132 (EMD Millipore, San Diego, CA), PYR-41 (ApexBio, Houston, 
TX), and P5091 (ApexBio, Houston, TX). The following proteasome fluorogenic substrates were used: Suc-LLVY-
AMC (Bachem, Torrance, CA; I-1395), Ac-WLA-AMC (Boston Biochem, Cambridge, MA; S-330), Ac-nLPnLD-
AMC (Bachem; I-1850), Ac-RLR-AMC (Boston Biochem; S-290), Ac-ANW-AMC (Boston Biochem; S-320), and 
Ac-PAL-AMC (Boston Biochem; S-310). Human recombinant Interferon-γ was purchased from eBioscience (San 
Diego, CA).
Cell viability assay. Cell viability was determined by CellTiter 96 AQueous One Solution Cell Proliferation 
assay (Promega, Madison, WI) according to the manufacturer’s protocol. Briefly, cells were seeded at a density of 
5,000–10,000 per well in 96-well plates and allowed 24 hours to attach. After cells were treated with the indicated 
concentrations of compounds for 72 hours, cell viability was measured using the reagent provided in the assay kit. 
Absorbance at 490 nm was measured using a SpectraMax M5 microplate reader (Molecular Devices, Sunnyvale, 
CA). Results were analyzed using GraphPad Prism (La Jolla, CA).
Proteasome activity profiling. Subunit-selective fluorogenic peptide substrates were used to measure the 
catalytic activities of individual catalytic subunits by monitoring the rate of substrate hydrolysis over time. Briefly, 
protein lysates were prepared using passive lysis buffer (Promega, Madison, WI) and diluted in 20S proteas-
ome assay buffer (20 mM Tris-HCl, 0.5 mM EDTA, 0.035% SDS, pH 8.0). Enzyme reactions were initiated by 
the addition of proteasome substrates. Substrates and concentrations were used as following: Suc-LLVY-AMC 
(β5/5i, 100 μM), Ac-WLA-AMC (β5, 20 μM), Ac-nLPnLD-AMC (β1,100 μM), Ac-RLR-AMC (β2/2i, 20 μM), 
Ac-ANW-AMC (β5i, 100 μM), and Ac-PAL-AMC (β1i activity, 100 μM). Fluorescence signals were measured 
over 1 hour at one reading per one minute using a SpectraMax M5 microplate reader at the excitation and emis-
sion wavelengths of 360 and 460 nm, respectively.
Immunoblotting analysis. Total cell lysates containing equivalent protein content were separated by 12% 
SDS-PAGE and transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA) via a semi-dry 
apparatus. Membranes were then blocked in 5% non-fat dry milk (Bio-Rad, Hercules, CA) in Tris-buffered saline 
with 0.05% Tween-20 (TBST) for 1 h at room temperature, followed by incubation with 3% BSA in TBST con-
taining the respective primary antibodies overnight at 4 °C: β1 (Enzo Life Sciences; PW8140), β2 (Enzo Life 
Sciences; PW8145), β5 (Thermo Scientific; PA1-977), β1i (Abcam; ab3328), β5i (Abcam; ab3329), β-actin (Novus 
Biologicals; NB600-501), and β2i (Santa Cruz; sc-133236; 3% milk-TBST used for dilution). Membranes were 
then washed five times with TBST and incubated with HRP (Horse radish peroxidase)-conjugated secondary 
antibodies for 1 hour at room temperature. Immunoreactive bands were visualized using SuperSignal West Femto 
Chemiluminescent Substrate (Thermo Scientific, Rockford, IL) and X-ray film (Thermo Scientific or GeneMate).
IFN-γ-induced transformation of the proteasome into the immunoproteasome. H727 and H23 
cells were treated with 150 U⋅ml−1 of IFN-γ or vehicle for 24 h. At the end of IFN-γ treatment, the cells were 
washed with PBS three times and then cultured for an additional 24 hours. Afterwards the cells were sub-cultured 
into a 96-well plate, and cell viability assays was performed using CellTiter 96 AQueous One Solution Cell 
Proliferation assay (Promega, Madison, WI) as described above. The remaining cells were then used for immu-
noblotting analysis and proteasome activity assays.
Knockdown of proteasome catalytic subunits. Cells were transfected with ON-TARGET Plus Smart 
Pool siRNAs (Dharmacon, Lafayette, CO) using Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, 
CA), according to the manufacturer’s instructions. H727 cells were plated in a 6-well plate at a density of 5 × 105 
cells per well and allowed at least 24 h to attach. Cells were then transfected with 100 nmole of siRNAs and 
Lipofectamine 2000. At 4 h post-transfection, serum-free Opti-MEM medium (Invitrogen, Carlsbad, CA) was 
replaced with complete medium and the cells were incubated for 48 h. The following siRNA pools were used: 
PSMB5 (L-004522-00-0020), PSMB7 (L-006021-00-0020), PSMB8 (L-006022-00-0020), PSMB9 (L-006023-
00-0005), and PSMB10 (L-006019-00-0020). For the negative control, human non-targeting scrambled siRNA 
(D-001810-10) was used.
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Statistics. Results are expressed as means ± S.D. Statistical significance of the observed differences was deter-
mined using Student’s t-test (with the Holm-Sidak method when appropriate). All statistical analyses were carried 
out using GraphPad Prism 7.04 (GraphPad Software).
Collection of primary MM samples. Cryopreserved MM primary cells isolated from the bone marrow or 
peripheral blood of patients with no reported history of PI treatment were purchased from Conversant Biologics 
(Huntsville, AL) and AllCells (Alameda, CA). CD138-positive cells were isolated from patient samples imme-
diately after thawing using human CD138 microbeads (Miltenyi Biotec), whole blood column kit (Miltenyi 
Biotec), MidiMACS magnetic separator (Miltenyi Biotec), and 30 µm MACS SmartStrainers (Miltenyi Biotec). 
Purified cells were plated on white 96-well cell culture plates at 40,000 cells per well in RPMI 1640 media supple-
mented with 10% FBS. Cells were treated with proteasome inhibitors for 48 hours before viability assessment via 
CellTiter-Glo Luminescent Cell Viability Assay (Bio-Rad).
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable 
request.
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